Kamada Ltd. (TLV:KMDA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.34B |
| Revenue (ttm) | 578.74M |
| Net Income (ttm) | 67.69M |
| Shares Out | 57.68M |
| EPS (ttm) | 1.16 |
| PE Ratio | 20.08 |
| Forward PE | 20.58 |
| Dividend | 0.73 (3.14%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 76,415 |
| Average Volume | 72,511 |
| Open | 2,357.00 |
| Previous Close | 2,357.00 |
| Day's Range | 2,316.00 - 2,376.00 |
| 52-Week Range | 2,061.00 - 3,045.00 |
| Beta | 0.14 |
| RSI | 55.09 |
| Earnings Date | Nov 10, 2025 |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Full Company ProfileFinancial Performance
In 2024, Kamada's revenue was $160.95 million, an increase of 12.93% compared to the previous year's $142.52 million. Earnings were $14.46 million, an increase of 74.58%.
Financial numbers in USD Financial StatementsNews
Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Q3 2025 Kamada Ltd Earnings Call Transcript
Q3 2025 Kamada Ltd Earnings Call Transcript
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar...
Kamada (KMDA) Q3 2025 Earnings Call Transcript
Kamada (KMDA) Q3 2025 Earnings Call Transcript
Kamada (KMDA) Misses Q3 Earnings Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Confirms 2025 Financial Outlook with Strong Growth Expectations
Kamada (KMDA) Confirms 2025 Financial Outlook with Strong Growth Expectations
Kamada GAAP EPS of $0.09 in-line, revenue of $47M misses by $0.22M; reaffirms FY outlook
Kamada reports Q3 GAAP EPS in line at $0.09; revenue grows 12.6% to $47M but misses expectations.
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ: CBAT) is likely to report quarterly loss at $0.04 per share on revenue of $39.27 million. • Townsquare Media (NYSE: TSQ) is estimated ...
An Overview of Kamada's Earnings
Kamada (NASDAQ: KMDA) will release its quarterly earnings report on Monday, 2025-11-10. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Kamada to report an earnin...
Kamada Q3 2025 Earnings Preview
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result
Countdown to Kamada (KMDA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Kamada (KMDA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e...
Should Value Investors Buy Kamada (KMDA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Kamada (KMDA) Begins Study on CYTOGAM for Transplant Patients
Kamada (KMDA) Begins Study on CYTOGAM for Transplant Patients
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade
The mean of analysts' price targets for Kamada (KMDA) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...
3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.
Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety
KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating levera...
Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ: EVO) is projected to report quarterly loss at $0.12 per share on revenue of $238.88 million. • Elbit Systems (NASDAQ: ESLT) is projected to repo...